Skip to main content

Table 2 Comparative analysis of main characteristics and treatment response in Systemic Lupus Erythematosus (SLE) patients with early and late onset nephritis

From: Comparison of lupus patients with early and late onset nephritis: a study in 71 patients from a single referral center

 Early onset N = 50Late onset N = 21P
Glomerulonephritis classification
 Class II5 (10%)3 (14.2%)0.79
 Class III10 (20%)3 (14.2%) 
 Class III+ V2 (4%)0 
 Class IV25 (50%)13 (61.9%) 
 Class IV+ V1 (2%)0 
 Class V7 (14%)2 (9.5%) 
Induction treatment
 Cyclophosphamide44 (88%)20 (95.2%)0.66
 MMF6 (12%)1 (4.7%) 
Maintenance treatment
 Azathioprine31 (62%)14 (66.6%)1.00
 MMF18 (36%)7 (33. 3%) 
Treatment response in 2 years
 Total remission30 (60%)12 (57.1%)0.35
 Partial remission10 (20%)2 (9.5%)
 Treatment failure10 (20%)7 (33. 3%)
Median creatinine (IQR)- mg/dL
 Initial0.98 (0. 6-1. 3)0.97 (0. 7-1. 3)0.94
 After 2 years0.80 (0. 7-1.1)0.74 (0. 6-1.0)0.45
Creatinine clearence (mL/min)
 Initial (median;IQR)83.5 (52. 3–120.6)82. 3 (52. 7-89.0)0.60
 After 2 years (mean ± SD)94.7 ± 38.797.0 ± 37.80.81
Positive anti-ds-DNA
 Initial20 (40%)13 (61.9%)0.09
 After 2 years14 (28%)9 (42.8%)0.22
Median 24 h proteinuria (g/L) (IQR)
 Initial2.9 (1. 7-5. 4)2.0 (1. 2-5.1)0.17
 After 2 years0.36 (0. 1-1.1)0.35 (0. 1-1.0)0.48
C3 (mg/dL)
 Initial (median; IQR)72.5 (46. 5-99.6)85.7 (56. 4–104.5)0.22
 After 2 years (mean ± SD)109. 4±29. 4103. 3±36. 30.45
Median C4 (IQR) (mg/dL)
 Initial11.9 (7. 9-21.8)12.0 (7.0–23.2)0.93
 After 2 years19.0 (13. 9-26.9)23.0 (13. 7-28.5)0.68
Hemoglobine (g/dL)
 Initial (mean ± SD)11.6 ± 2.212.8 ± 1.50.02
 After 2 years (median;IQR)13.0 (12.0–14.1)12.6 (12.0–13.8)0.58
SLEDAI
 Initial (mean ± SD)14.8 ± 5. 413.2 ± 6.10.28
 After 2 years (mean ± SD)5.8± 4.66. 4± 4.80.59
Median SLICC/ACR DI (IQR)
 Initial0 (0–1)0 (0–1)0.93
 After 2 years0 (0–2)1.0 (0–2)0.41
 Interval (years) until first recurrence – median (IQR)4.5 (2. 2-6.7)3.0 (1.0–5.0)0.07
  1. N number, IQR interquartile range, SD standard deviation, MMF mophetyl mycophenolate, SLEDAI Systemic lupus erythematosus disease activity index, SLICC/ACR DI Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index